Myriad Genetics

OverviewSuggest Edit

Myriad Genetics is a genetic testing and precision medicine company. It specializes its products, capabilities, and expertise in three areas: oncology, women's health, and mental health. The company develops molecular diagnostic tests designed to analyze genes and their expression levels to assess an individual’s risk for developing disease, determine a patient’s likelihood of responding to a particular drug, or assess a patient’s risk of disease progression.
TypePublic
Founded1991
HQSalt Lake City, UT, US
Websitemyriad.com
Employee Ratings3.6
Overall CultureB-

Latest Updates

Employees (est.) (Dec 2021)2,400(-11%)
Job Openings125
Revenue (FY, 2021)$690.6 M(+9%)
Share Price (Jun 2022)$18.4
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Myriad Genetics

Paul J. Diaz

Paul J. Diaz

President & CEO
Eric Santa

Eric Santa

Chief Growth Officer
Kevin R. Haas

Kevin R. Haas

Chief Technology Officer
Bryan Riggsbee

Bryan Riggsbee

Chief Financial Officer
Jayne B. Hart

Jayne B. Hart

Chief People Officer
Pamela Wong

Pamela Wong

Chief Legal Officer
Show more

Myriad Genetics Office Locations

Myriad Genetics has offices in Salt Lake City, Austin, Mason, South San Francisco and in 7 other locations
Salt Lake City, UT, US (HQ)
320 Wakara Way
Austin, TX, US
3300 Duval Rd
Mason, OH, US
6960 Cintas Blvd
South San Francisco, CA, US
180 Kimball Way
South San Francisco, CA, US
341 Oyster Point Blvd
Issy-les-Moulineaux, FR
41 Rue Camille Desmoulins
Show all (12)

Myriad Genetics Financials and Metrics

Myriad Genetics Revenue

Embed Graph
View revenue for all periods
Myriad Genetics's revenue was reported to be $690.6 m in FY, 2021
USD

Revenue (Q1, 2022)

164.9m

Gross profit (Q1, 2022)

116.9m

Gross profit margin (Q1, 2022), %

70.9%

Net income (Q1, 2022)

(20.5m)

EBIT (Q1, 2022)

(25.6m)

Market capitalization (29-Jun-2022)

1.5b

Closing stock price (29-Jun-2022)

18.4

Cash (31-Mar-2022)

165.2m

EV

1.4b
Myriad Genetics's current market capitalization is $1.5 b.
Annual
USDFY, 2019FY, 2020FY, 2021

Revenue

851.1m638.6m690.6m

Revenue growth, %

10%

Cost of goods sold

201.0m186.1m197.6m

Gross profit

650.1m452.5m493.0m
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

186.3m195.1m164.0m173.1m189.4m167.3m164.9m

Cost of goods sold

49.7m49.6m50.1m50.3m53.7m47.8m48.0m

Gross profit

136.6m145.5m113.9m122.8m135.7m119.5m116.9m

Gross profit Margin, %

73%75%69%72%71%71%
Annual
USDFY, 2019FY, 2020FY, 2021

Cash

93.2m163.7m258.4m

Accounts Receivable

133.9m68.1m91.3m

Prepaid Expenses

16.6m13.8m20.0m

Inventories

31.4m29.1m15.3m
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

89.9m81.2m121.0m148.9m118.4m295.2m165.2m

Accounts Receivable

4.8m118.3m102.5m94.1m94.8m93.6m101.7m

Prepaid Expenses

14.0m16.2m12.5m13.9m17.7m20.2m18.8m

Inventories

28.1m28.1m30.8m24.6m17.7m18.6m15.6m
Annual
USDFY, 2019FY, 2020FY, 2021

Net Income

4.6m(199.5m)(27.2m)

Depreciation and Amortization

73.0m72.0m62.8m

Inventories

8.0m1.6m1.6m

Accounts Payable

1.1m(10.7m)9.2m
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(20.6m)(28.9m)(144.1m)(39.5m)(44.2m)(19.6m)(20.5m)

Depreciation and Amortization

18.2m36.4m54.3m18.4m35.3m49.5m13.0m

Inventories

3.1m2.6m2.4m(800.0k)(1.6m)(200.0k)

Accounts Payable

(9.3m)(11.3m)(2.1m)300.0k8.1m(4.8m)(3.2m)
USDFY, 2019

EV/EBIT

288.5 x

EV/CFO

26.2 x

Revenue/Employee

327.3k

Debt/Equity

0.2 x

Debt/Assets

0.2 x

Financial Leverage

1.4 x

P/E Ratio

463.0
Show all financial metrics

Myriad Genetics Operating Metrics

FY, 2019Mar, 2020FY, 2021

Products

1110

Publications to Date

1 k

Countries

143

Trademarks

67

Myriad Genetics Acquisitions / Subsidiaries

Company NameDateDeal Size
CounsylJuly 31, 2018$405.9 m
Myriad Women’s HealthMay 29, 2018$408.6 m
Assurex Health, Inc.August 04, 2016$225 m
Myriad NeuroscienceAugust 03, 2016$351.6 m
Sividon DiagnosticsMay 31, 2016$56 m
Privatklinik Dr. Robert SchindlbeckFebruary 27, 2015$20.1 m
Crescendo BioscienceFebruary 04, 2014
Myriad AutoimmuneFebruary 04, 2014$270 m
Rules-Based MedicineApril 27, 2011$80 m
Javelin PharmaceuticalsDecember 18, 2009$95 m
Show more

Myriad Genetics Revenue Breakdown

Embed Graph

Myriad Genetics revenue breakdown by business segment: 96.5% from Molecular Diagnostic Testing and 3.5% from Other

Myriad Genetics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Myriad Genetics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Myriad Genetics Online and Social Media Presence

Embed Graph

Myriad Genetics Company Culture

  • Overall Culture

    B-

    70/100

  • CEO Rating

    D+

    61/100

  • Compensation

    B

    75/100

Learn more on Comparably

Myriad Genetics News and Updates

Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first environmental, social and governance (ESG) report, highlighting increased efforts to support a healthy, equitable and sustainable so…

Epic, Myriad Genetics collaborate on EHR integration for genetic testing

Myriad Genetics is working with Epic to integrate its genetic test technology into the electronic health record used by more than 600,000 physicians. WHY IT MATTERS The integration enables end-to-end workflows for healthcare providers to order Myriad tests and review their results directly within th…

Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration

SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company, to integrate Myriad’s full line of genetic tests with Epic’s expan…

Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

SALT LAKE CITY, June 09, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation and growth plan during a fireside chat at the Goldman Sachs 43rd Annual Global H…

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide and…

Shadowbox technology facilitated orders of Myriad Genetics germline diagnostic, increasing volume by more than 800%

SAN DIEGO, May 17, 2022 /PRNewswire/ -- Shadowbox, a leading innovator in healthcare automation solutions, is excited to announce the results of a case study with leading genetic testing company, Myriad Genetics, that not only eliminated cumbersome manual work, but also increased...
Show more

Myriad Genetics Blogs

The Next Wave of the Pandemic

When the Covid-19 pandemic first hit, many patients took what they thought would be a temporary break from preventive care visits to the doctor. However, more than two years later, people still aren’t coming in for their annual physicals and screenings at pre-pandemic levels. And with staff shortage…

New Guidelines from AUA and ASTRO Support Inclusion of Genomic Testing in Localized Prostate Cancer

By Thomas Slavin, M.D., chief medical officer, Myriad Genetics  According to the American Cancer Society, in 2022 more than 268,000 men in the United States will be diagnosed with prostate cancer, making it the second most common cancer in men. Tragically, close to 35,000 men will die from prostate …

Making Genetic Testing More Inclusive

Myriad Genetics’ innovative approach to genetic testing gives more women the information they need to stay healthy. By FastCo Works For the past 30 years, Myriad Genetics has been involved in genetic testing to help women determine their risk of breast cancer. Typically, about 5% of women test posit…

The Future of Genetic Testing: How a Love of DNA Led to More Comprehensive Tests

For more than 30 years now, scientists at Myriad Genetics have been finding creative ways to coax new information out of human genes. The love for exploring the human genome has given us the foundation on which to build genetic tests that help people understand their risk of cancer, which mental hea…

During Women’s History Month, We’re Celebrating Women’s Contributions at Myriad Genetics

Throughout March we’re celebrating Women’s History Month, a recognition of the countless contributions women have made here in the U.S. and around the world. This year, the theme is “providing healing, promoting hope” — a concept that really resonates with our team and our push to deliver better hea…

New Enhancements to Noninvasive Prenatal Screening (NIPS)

Myriad Genetics was honored to participate in one of the most important conferences for Maternal Fetal Medicine specialists and other medical providers focused on the health of mothers, pregnancies, and babies. At the Society for Maternal-Fetal Medicine’s 42nd Annual Pregnancy Meeting, Myriad Geneti…
Show more

Myriad Genetics Frequently Asked Questions

  • When was Myriad Genetics founded?

    Myriad Genetics was founded in 1991.

  • Who are Myriad Genetics key executives?

    Myriad Genetics's key executives are Paul J. Diaz, Eric Santa and Kevin R. Haas.

  • How many employees does Myriad Genetics have?

    Myriad Genetics has 2,400 employees.

  • What is Myriad Genetics revenue?

    Latest Myriad Genetics annual revenue is $690.6 m.

  • What is Myriad Genetics revenue per employee?

    Latest Myriad Genetics revenue per employee is $287.8 k.

  • Who are Myriad Genetics competitors?

    Competitors of Myriad Genetics include Asuragen, Progenity and Foundation Medicine.

  • Where is Myriad Genetics headquarters?

    Myriad Genetics headquarters is located at 320 Wakara Way, Salt Lake City.

  • Where are Myriad Genetics offices?

    Myriad Genetics has offices in Salt Lake City, Austin, Mason, South San Francisco and in 7 other locations.

  • How many offices does Myriad Genetics have?

    Myriad Genetics has 12 offices.